A portfolio of start-ups is created and an investment base is sought for the entire package. The system used at Karolinska Institutet is unique in the world, and creates better chances of success as well as healthy earnings for the investors.
The university is forever generating new science of considerable market potential. However, the lack of venture capital to cover the cost of early product development is just one of the problems hampering the commercialisation of scientific discoveries.
Karolinska Institutet has solved this problem in a unique way by forming portfolio companies. To date two such companies have been set up, named Karolinska Development I and II. Karolinska Development I comprises 16 start-ups and Karolinska Development II 18. Investors support the entire portfolio, and since their capital is invested in several different companies, their risks decrease in inverse proportion to their chances of success. The portfolio companies are supported by Karolinska Development until they are ready to launch their applications onto the market.
“Pretty much all universities help their research teams to market their discoveries,” says Ola Flink, investment manager at Karolinska Development. “We’ve solved the main problem of getting financing for such early discoveries in a hugely successful way. Our solution gives investors a greater chance of generating healthy returns as they invest their money in several different companies.”
Mr Ola Flink can be contact on +46-70-350 39 94, or at ola.flink@kab.ki.se
28 February, 2023 - Karolinska Institutet
Following a successful pilot study, an online anonymous treatment program aimed at reducing child sexual abuse by providing treatment to individuals who exhibit sexual urges towards children is being launched across the EU. It is now available in Swedish, German, and Portuguese as well as in an updated English version. The treatment program, which has […]
29 April, 2021 - Karolinska Institutet
Researchers at Karolinska Institutet and the Public Health Agency of Sweden have studied newborn babies whose mothers tested positive for SARS-CoV-2 during pregnancy or childbirth. The results show that although babies born of test-positive mothers are more likely to be born early, extremely few were infected with COVID-19. The study, which is published in the […]
27 April, 2020 - Karolinska Institutet
Only about five per cent of the babies born to mothers with hepatitis C are themselves infected by the disease. A possible reason for this low figure is that the baby’s immune system has already destroyed the virus before birth. A new study from researchers at KI and published in the journal Gut reveals clear […]
7 April, 2020 - Karolinska Institutet
People with celiac disease have increased risk of dying prematurely, despite increased awareness of the disease in recent years and better access to gluten-free food. This is according to a new study from Karolinska Institutet in Sweden and Columbia University in the U.S. published in the prestigious journal JAMA. Celiac disease was linked to increased […]
Expertsvar, The Swedish Research Council, Hantverkargatan 11B, Stockholm SWEDENPhone +46(0)8 546 44 000
P.O. Box 1035, SE-101 38 Stockholm, expertsvar@vr.se
Information about cookies will open in a new window
